- OncoHelixwill now offer the validated ClarityDX Prostate Risk Score to healthcare providers and their patients suspected of having aggressive prostate cancer.
- ClarityDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer.
EDMONTON, Alberta & CALGARY, Alberta
Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, and OncoHelix, a leader in precision diagnostics, today announced their partnership to provide ClarityDX Prostate® to healthcare providers and men in the Middle East.
ClarityDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy following a high prostate-specific antigen (PSA) test result or abnormal digital rectal examination (DRE) result.
OncoHelix provides advanced molecular diagnostics and immune profile testing to the Middle East and North Africa (MENA) region through OncoHelix-coLAB, a state-of-the-art laboratory within Burjeel Medical City, Abu Dhabi. This facility is a joint venture between OncoHelix and Burjeel Holdings, one of the largest healthcare providers in the Middle East. The OncoHelix-coLAB facility will now also provide Nanostics’ ClarityDX Prostate diagnostic tool to men at risk of having aggressive prostate cancer. The addition of this test will further enhance patient diagnostics and treatment outcomes in the region.
“Partnering with OncoHelix, another Alberta-based company, to bring ClarityDX Prostate to men in the Middle East really shows how relevant Alberta-developed technology has become to the world,” said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “ClarityDX Prostate is a powerful diagnostic tool that can help identify men with aggressive prostate cancer early. We want all men to benefit from early detection leading to better outcomes.”
“We are thrilled to partner with Nanostics to bring the ClarityDX Prostate test to the Middle East. This advanced diagnostic tool will empower healthcare providers with better, data-driven insights, enabling earlier detection and more targeted treatment for men at risk of aggressive prostate cancer in the region,” said Faisal Khan, CEO of OncoHelix.
